pharma · Hypertension
Innovent Biologics
Innovent Biologics (Suzhou) Co.
Innovent Biologics (Suzhou) is a pharma organization headquartered in CN. Primary therapeutic focus areas include Hypertension. NovaPharmaNews links 2 clinical program(s), 0 drug profile(s), and 0 patent record(s) to thi
Company details
- Status
- Public
- HQ
- Suzhou, CN
- Founded
- 2011
- Employees
- 850
- Programs
- 2
- Drugs
- 3
- Patents
- 0
Quick answer
Innovent Biologics (Suzhou) is a pharma organization headquartered in CN. Primary therapeutic focus areas include Hypertension. NovaPharmaNews links 2 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and USPTO sources. Pipeline phase mix: phase 2 (1), phase 1 (1).
Company snapshot
Innovent Biologics, Inc. (Innovent; [Chinese](en.wikipedia.org/wiki/Simplified_Chinese): 信达生物制药; [pinyin](en.wikipedia.org/wiki/Pinyin): Xìndá shēngwù zhìyào) is a [publicly listed](en.wikipedia.org/wiki/Publicly_listed) Chinese [biopharmaceutical](en.wikipedia.org/wiki/Biopharmaceutical) company that is headquartered in [Suzhou](en.wikipedia.org/wiki/Suzhou), [Jiangsu](en.wikipedia.org/wiki/Jiang
- 2 active pipeline program(s) linked via ClinicalTrials.gov.
- 2 trial update(s) in the last 12 months.
Public regulatory, clinical, patent, and corporate records for Innovent Biologics. Not investment advice.
Catalysts
Upcoming readouts, regulatory dates, and congress activity.
- deal
Pfizer and Innovent's $10B Cancer Drug Deal: Key Insights
- approval
Innovent Biologics and Pfizer: A $10.5B Oncology Partnership
- approval
Innovent Biologics and Pfizer's $10.5 Billion Cancer Drug Deal
- approval
Innovent Biologics Shares Surge 10% Following Pfizer Deal
- deal
China: The Innovation Factor – Implications for Pharma BD and Investors
- approval
Pharma bets on PD-1/VEGF bispecifics: Is lung cancer the wrong target?
Recent coverage
Pharma bets on PD-1/VEGF bispecifics: Is lung cancer the wrong target?
While many drugmakers are focused on lung cancer for PD-1/VEGF bispecifics, emerging evidence shows the liver may offer higher value. This analysis covers the mechanism, key players, and strategic implications for pharma teams.
China: The Innovation Factor – Implications for Pharma BD and Investors
China has emerged as a global innovation powerhouse, now leading in 37 of 44 critical technologies. This article examines what this means for pharmaceutical deal-making, investment decisions, and competitive strategy for BD teams and executives.
Innovent Biologics Shares Surge 10% Following Pfizer Deal
Innovent Biologics' shares have surged by 10% following a major partnership with Pfizer valued at up to $10.5 billion. This article analyzes the market impact and future implications.
Innovent Biologics and Pfizer's $10.5 Billion Cancer Drug Deal
Innovent Biologics and Pfizer have entered a significant $10.5 billion deal for a cancer drug, marking a pivotal moment in China's biotech landscape. This article explores the implications for the pharmaceutical industry.
Top assets
Lead pipeline drugs
- Marketed / approved
- Marketed / approved
- Marketed / approved
- Phase 2
Momentum signals
Momentum
Proprietary activity score for Innovent Biologics.
2 active signals
Signal breakdown
- Clinical trials
- Nova articles
- Patents filed
- FDA actions
- SEC filings
- Conference presentations
- Pipeline advances
Competitive landscape
Recent activity
Recent activity
Latest pipeline, patent, and corporate events for Innovent Biologics.
- Clinical update
- Clinical update
Quick answers
Common questions about this sponsor — for analysts and search.
-
What is Innovent Biologics?
-
Is Innovent Biologics publicly traded?
-
What drugs does Innovent Biologics develop or market?
-
What are the latest developments for Innovent Biologics?
-
What therapeutic areas does Innovent Biologics focus on?
Therapeutic focus
Therapeutic area distribution
Pipeline concentration by therapeutic area from linked clinical programs.